Current Report Filing (8-k)
24 January 2017 - 2:23PM
Edgar (US Regulatory)
UNITES
STATES
SECURITIES AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): January 24, 2017
NEPHROS,
INC.
(Exact
name of Registrant as Specified in its Charter)
Delaware
|
|
001-32288
|
|
13-3971809
|
(State
or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(IRS
Employer
Identification No.)
|
41
Grand Avenue, River Edge, New Jersey 07661
(Address
of principal executive offices, including ZIP code)
(201)
343-5202
(Registrant’s
telephone number, including area code)
Not
Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
[ ] Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item
2.02. Results of Operations and Financial Condition.
On
January 24, 2017, Nephros, Inc. (the “Company”) issued a press release in which it disclosed its approximate revenue
for the fiscal year ended December 31, 2016. A copy of this press release is furnished herewith as Exhibit 99.1. Pursuant to the
rules and regulations of the Securities and Exchange Commission, such exhibit and the information set forth therein and in this
Item 2.02 have been furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange
Act of 1934, as amended (the “Exchange Act”), or otherwise subject to liability under that section nor shall they
be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as
shall be expressly set forth by specific reference in such filing regardless of any general incorporation language.
Item
9.01. Financial Statements and Exhibits.
(d)
Exhibits.
Exhibit
No.
|
|
Description
|
|
|
|
99.1
|
|
Nephros,
Inc. Press Release dated January 24, 2017.
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
Nephros,
Inc.
|
|
|
|
Dated:
January 24, 2017
|
By:
|
/s/
Daron Evans
|
|
|
Daron
Evans
|
|
|
President
& Chief Executive Officer
|
Index
to Exhibits Filed with this Report
Exhibit
No.
|
|
Description
|
|
|
|
99.1
|
|
Nephros,
Inc. Press Release dated January 24, 2017.
|